中国实用内科杂志2025，Vol.45Issue(1)：32-47,16.DOI:10.19538/j.nk2025010106
促血小板生成药物治疗再生障碍性贫血专家共识
Expert consensus on platelet-stimulating agents for the treatment of aplastic anemia
摘要
Abstract
Aplastic anemia is an immune-mediated bone marrow failure disease.In recent years,platelet-stimulating agents have become one of the important options for the treatment of aplastic anemia.Platelet-stimulating agents include thrombopoietin receptor agonists(Eltrombopag,Hetrombopag,Romiplostim,Avatrombopag,and Lusutrombopag)and recombinant human thrombopoietin.By stimulating the proliferation and differentiation of hematopoietic stem cells,these agents enhance bone marrow function,accelerate and strengthen hematologic remission in aplastic anemia patients,reduce the need for transfusions,and improve quality of life.This consensus,based on domestic and international literature,provides reference recommendations for the application of platelet-stimulating agents in the treatment of aplastic anemia,aiming to standardize and guide their use in clinical practice.关键词
再生障碍性贫血/促血小板生成药物/血小板生成素受体激动剂/疗效/安全性Key words
aplastic anemia/platelet-stimulating agents/thrombopoietin receptor agonists/efficacy/safety分类
医药卫生引用本文复制引用
中华医学会血液学分会红细胞疾病(贫血)学组,韩冰,张连生..促血小板生成药物治疗再生障碍性贫血专家共识[J].中国实用内科杂志,2025,45(1):32-47,16.基金项目
中国医学科学院临床与转化医学研究专项(2023-12M-C&T-B-013) （2023-12M-C&T-B-013）
国家自然科学基金(82370121) （82370121）
北京自然科学基金(7232109) （7232109）
中央高水平医院临床科研业务费(2022-PUMCH-C-026,2022-PUMCH-D-002) （2022-PUMCH-C-026,2022-PUMCH-D-002）
中国医学科学院医学与健康科技创新工程(重大协同创新项目) （重大协同创新项目）
中国罕见病的精准诊疗研究(CIFMS2021-I2M-1-003) （CIFMS2021-I2M-1-003）
